z-logo
open-access-imgOpen Access
Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo-β-Lactamase-Producing Enterobacteriaceae : Report from the SENTRY Antimicrobial Surveillance Program
Author(s) -
Mariana Castanheira,
Hélio S. Sader,
Lalitagauri M. Deshpande,
Thomas R. Fritsche,
Ronald N. Jones
Publication year - 2008
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01114-07
Subject(s) - tigecycline , microbiology and biotechnology , broth microdilution , antimicrobial , amikacin , enterobacteriaceae , carbapenem resistant enterobacteriaceae , polymyxin , polymyxin b , imipenem , biology , colistin , antibiotic resistance , antibiotics , minimum inhibitory concentration , escherichia coli , biochemistry , gene
A total of 104 carbapenemase (serine- and metallo-beta-lactamase [MbetaL])-producing strains of the Enterobacteriaceae family collected from 2000 to 2005 in medical centers distributed worldwide were tested against tigecycline and 25 comparators by reference broth microdilution methods. The most frequent carbapenemase was KPC-2 or -3 (73 strains), followed by VIM-1 (14), IMP-1 (11), SME-2 (5), and NMC-A (1). All serine carbapenemases were detected in the United States, while MbetaL-producing strains were isolated in Europe. Carbapenemase-producing Enterobacteriaceae showed high rates of resistance to most antimicrobial agents tested. The rank order of in vitro activity against these strains was as follows: tigecycline (100.0% susceptible) > polymyxin B (88.1%) > amikacin (73.0%) > imipenem (37.5%). Tigecycline was very active (MIC(90), 1 microg/ml) against this significant, contemporary collection of well-characterized strains and appears to be an excellent option compared to the polymyxins for treatment of infections caused by these multidrug-resistant Enterobacteriaceae.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here